US At-home Respiratory Care Services Market Size, Share, Trends and Forecast by Therapy, Indication, and Region, 2026-2034

US At-home Respiratory Care Services Market Summary:

The US at-home respiratory care services market size reached USD 16,129.85 Million in 2025. The market is projected to reach USD 32,416.02 Million by 2034, growing at a CAGR of 8.06% during 2026-2034. The market is driven by the accelerating transition toward home-based healthcare delivery, widespread adoption of value-based care models transforming operational practices across home health agencies, and the quick integration of digital health technology that make telehealth services and remote patient monitoring possible. Demand is still being driven by the aging population and the rising incidence of long-term respiratory diseases like COPD, asthma, and sleep apnea. At the same time, technology advancements in ventilation equipment, nebulizers, and portable oxygen concentrators improve patient accessibility and convenience. Favorable Medicare policies supporting home health services and the growing emphasis on reducing hospital readmissions are further expanding the US at-home respiratory care services market share.

US At-home Respiratory Care Services Market Outlook (2026-2034):

The US at-home respiratory care services market is expected to grow significantly over the course of the forecast period due to changes in healthcare delivery methods, technological developments, and demographic shifts. The aging population, with Americans aged 65 and older projected to comprise nearly 22% of the total population by 2034, will drive sustained demand for chronic disease management services delivered in home settings. Continued innovation in connected respiratory devices, artificial intelligence-enabled monitoring systems, and telehealth platforms will enhance clinical outcomes while improving patient convenience and reducing healthcare system costs. Furthermore, Medicare's ongoing emphasis on value-based reimbursement models incentivizes providers to prioritize quality outcomes and care coordination, positioning home-based respiratory services as a cost-effective alternative to institutional care settings while supporting the market's positive trajectory.

Impact of AI:

Artificial intelligence is revolutionizing at-home respiratory care services by enabling predictive analytics, automated monitoring, and personalized treatment optimization. AI-powered algorithms embedded in smart inhalers track medication adherence patterns and provide real-time feedback to patients and clinicians, facilitating early intervention before respiratory symptoms escalate. Remote patient monitoring platforms leverage machine learning to analyze continuous respiratory data streams, identifying subtle changes in breathing patterns that may indicate impending exacerbations. Additionally, AI-driven diagnostic tools accelerate sleep apnea detection through at-home testing devices, reducing diagnosis timelines from weeks to days while improving accessibility for underserved populations.

Market Dynamics:

Key Market Trends & Growth Drivers:

Accelerating Transition to Home-Based Respiratory Care Delivery

The healthcare industry is experiencing a fundamental shift from institutional to home-based care delivery, driven by patient preferences, cost considerations, and clinical evidence demonstrating comparable or superior outcomes for many respiratory conditions when managed in familiar home environments. This transformation has been particularly pronounced following the COVID-19 pandemic, which accelerated the adoption of home health services and demonstrated the feasibility of delivering complex respiratory therapies outside traditional hospital settings. Patients increasingly prefer receiving care at home, where they experience greater comfort, maintain daily routines, and avoid exposure to hospital-acquired infections. Medicare and private insurers actively support this transition through enhanced reimbursement for home health services and value-based payment models that reward providers for keeping patients healthy at home rather than readmitting them to hospitals. The US at-home respiratory care services market growth is further strengthened by technological advancements in portable medical devices that enable sophisticated therapies to be administered safely in home settings. In January 2025, ResMed announced the national availability of its FDA-cleared NightOwl home sleep-apnea test across the United States, enabling patients to conduct diagnostic testing in the comfort of their homes rather than in clinical sleep laboratories. This development exemplifies how diagnostic capabilities previously confined to healthcare facilities are now accessible to patients at home, removing barriers to timely diagnosis and treatment initiation. Home health referrals originating from hospitals increased to 31% in 2024, reflecting healthcare systems' strategic focus on transitioning high-acuity patients to home-based care models that reduce costs while maintaining clinical quality

Widespread Adoption of Value-Based Care Models Transforming Operational Practices

Value-based care has emerged as the dominant trend reshaping the home respiratory care services landscape, fundamentally altering how providers structure operations, measure success, and receive reimbursement. Value-based care links remuneration to clinical results, patient satisfaction, and cost effectiveness, in contrast to conventional fee-for-service models that pay clinicians according to the amount of services rendered. This paradigm shift incentivizes respiratory care providers to invest in preventive services, care coordination, and technology platforms that enable proactive patient monitoring and early intervention before conditions deteriorate. The financial alignment created by value-based contracts encourages providers to optimize resource utilization, reduce unnecessary hospitalizations, and improve medication adherence through enhanced patient engagement strategies. According to 70% of home care leaders surveyed, the implementation of value-based care in 2023 resulted in major operational changes for their organizations. These changes included the hiring of care coordinators, the deployment of remote monitoring technology, and the establishment of data analytics capabilities to track patient outcomes. The industry's strategic commitment to this payment shift is demonstrated by the fact that over 60% of home care executives predict value-based care contracts to generate at least half of their income by 2027. In order to replace the COVID-19 reporting requirements for long-term care institutions with more comprehensive respiratory illness monitoring, the Centers for Medicare & Medicaid Services announced new data reporting criteria in November 2024. Facilities must electronically submit COVID-19, influenza, and respiratory syncytial virus information via the CDC's National Healthcare Safety Network on a weekly basis starting on January 1, 2025. This regulatory evolution demonstrates CMS's commitment to comprehensive respiratory disease surveillance and quality measurement, providing the data infrastructure necessary for value-based payment models to assess and reward provider performance based on population health outcomes.

Integration of Digital Health Technologies and Remote Patient Monitoring

The convergence of telecommunications, medical devices, and data analytics is revolutionizing at-home respiratory care through sophisticated remote patient monitoring platforms and telehealth services. Digital health technologies enable continuous monitoring of vital respiratory parameters including oxygen saturation, respiratory rate, breathing patterns, and medication usage, transmitting real-time data to clinical teams who can detect concerning trends and intervene proactively before minor issues escalate into acute events requiring hospitalization. This capability has proven particularly valuable for managing chronic conditions like COPD and asthma, where early detection of exacerbations significantly improves outcomes and reduces healthcare costs. Connected respiratory devices generate actionable intelligence through artificial intelligence algorithms that learn individual patient baselines, identify deviations from normal patterns, and alert clinicians to patients requiring immediate attention, enabling efficient resource allocation and prioritized interventions. Telehealth consultations complement remote monitoring by providing patients convenient access to respiratory therapists, pulmonologists, and nurses for medication adjustments, symptom management guidance, and patient education without requiring office visits. The regulatory environment increasingly supports these innovations, with Medicare expanding reimbursement for remote patient monitoring services and federally qualified health centers gaining authorization to bill for RPM under the 2024 Physician Fee Schedule. In October 2024, Modivcare announced a collaboration with Tenovi to deliver Adherium's Hailie Smart Inhalers for enhanced patient care in chronic respiratory diseases. The partnership combines Tenovi's Cellular Gateway technology with Modivcare's chronic condition management services to improve medication adherence for patients with severe asthma while reducing total cost of care. This integration exemplifies how digital health platforms unite medical devices, telecommunications infrastructure, and clinical services to create comprehensive care solutions that address the full continuum of patient needs beyond episodic interactions.

Key Market Challenges:

Severe Workforce Shortages and Retention Issues Among Respiratory Therapists

The respiratory care profession confronts an unprecedented workforce crisis that threatens the industry's capacity to meet growing demand for home-based services. According to a 2021 National Board for Respiratory Care research, enrollment in respiratory care education programs has decreased by 27% since 2010, and approximately 100,000 respiratory therapists are expected to leave the field by the end of this decade. These dynamics create a supply-demand imbalance that manifests as prolonged job vacancies, increased reliance on expensive contract labor, and compromised service quality when remaining staff members face unsustainable workloads. The COVID-19 pandemic exacerbated these challenges, exposing respiratory therapists to extreme occupational stress, emotional trauma from witnessing mass casualties, and physical exhaustion from extended work hours during surge periods. Job openings for respiratory therapists rose by 31% between 2019 and 2020, however burnout rates skyrocketed as a result of understaffing, failure to finish tasks, and a lack of organizational support. The largest obstacle for home care providers in 2024 is still staffing, as many organizations are unable to take on new clients despite high demand because they do not have enough clinical staff to provide services in a safe and efficient manner. The competitive labor market has driven sharp increases in compensation costs as agencies compete for limited talent pools, with travel respiratory therapist contracts commanding premium rates that strain organizational budgets. This workforce shortage creates a vicious cycle where inadequate staffing contributes to burnout, burnout causes experienced therapists to leave the profession, and departures further worsen staffing ratios, perpetuating the crisis. Educational capacity constraints compound the problem, as respiratory therapy programs cannot rapidly scale enrollment due to limited faculty, clinical training site availability, and accreditation requirements, meaning the pipeline of new graduates remains insufficient to replace retiring workers and fill newly created positions driven by demographic growth and expanded home care utilization.

Medicare Reimbursement Pressures and Payment Cuts

Home respiratory care providers operate within a challenging reimbursement environment characterized by payment rate reductions, administrative complexity, and uncertainty regarding future policy directions. In 2020, the Centers for Medicare & Medicaid Services introduced the Patient-Driven Groupings Model, which significantly changed the way home health organizations are paid by moving away from a therapy-focused system and toward one that is based on patient characteristics and clinical needs. While intended to better align reimbursement with resource requirements, PDGM created financial disruption across the industry as CMS determined Medicare had overpaid agencies during the transition period and began imposing permanent behavioral adjustment reductions to recapture those overpayments. In order to account for the PDGM transition, CMS finalized a permanent prospective adjustment of negative 1.975% for calendar year 2025. This represents the third year in a row of payment reductions intended to counteract perceived overpayments from 2020 and 2021. Although CMS finalized a 2.7% market basket update, the net effect of combining the inflation adjustment with behavioral offsets and other payment modifications resulted in only a 0.5% increase compared to 2024, barely keeping pace with operational cost inflation for labor, supplies, and overhead expenses. These modest payment increases follow a 2.2% reduction in 2023 and only an 0.8% increase in 2024, creating a multi-year pattern of constrained reimbursement that compresses margins and limits providers' ability to invest in workforce development, technology infrastructure, and service expansion. The administrative burden associated with Medicare compliance has intensified, with agencies required to implement new data reporting standards for respiratory illnesses, submit quality measures, and navigate complex billing rules that vary by payer and geographic market. Private insurers frequently adopt Medicare's payment methodologies and rates as benchmarks for their own reimbursement policies, meaning Medicare cuts create ripple effects throughout payer mix and limit providers' ability to offset public program shortfalls with commercial revenue.

Regulatory Compliance Complexities and Device Safety Concerns

The at-home respiratory care services sector operates within an intricate regulatory framework spanning federal and state jurisdictions, with oversight from the Food and Drug Administration, Centers for Medicare & Medicaid Services, state licensing boards, and accreditation organizations imposing overlapping and sometimes conflicting requirements. Compliance demands substantial organizational resources for policy documentation, staff training, quality auditing, and regulatory reporting, creating particular challenges for smaller independent providers who lack dedicated compliance departments. The Philips Respironics device recall, which began in June 2021 and affected more than 15 million CPAP machines, BiPAP devices, and ventilators worldwide due to foam degradation releasing toxic particles, has profoundly disrupted the industry and heightened regulatory scrutiny of respiratory device safety. The FDA received more than 100,000 reports of malfunctions, injuries, and 561 deaths associated with recalled Philips devices as of January 2024, prompting the agency to impose a consent decree preventing Philips from selling sleep and respiratory care products in the United States until completing comprehensive remediation programs and establishing enhanced quality systems. This consent decree resulted in Philips discontinuing sales of all sleep and respiratory care devices in the US market in January 2024, creating severe supply shortages that left patients unable to obtain prescribed equipment and forcing competitors like ResMed to dramatically scale production to meet surging demand. The regulatory fallout from the Philips recall extends beyond that single manufacturer, as the FDA intensified inspections and enforcement actions across the respiratory device industry, requiring enhanced post-market surveillance, more rigorous clinical testing protocols, and expedited adverse event reporting. These heightened safety standards, while necessary to protect patients, impose additional compliance costs and extend product development timelines for all manufacturers and providers.

US At-home Respiratory Care Services Market Report Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the US at-home respiratory care services market, along with forecasts at the country and regional levels for 2026-2034. The market has been categorized based on therapy and indication.

Analysis by Therapy:

• Oxygen Therapy
• Non-invasive Ventilation
• Sleep Apnea Care
• Aerosol Therapy and Others

The report has provided a detailed breakup and analysis of the market based on the therapy. This includes oxygen therapy, non-invasive ventilation, sleep apnea care, and aerosol therapy and others.

Analysis by Indication:

• Chronic Obstructive Pulmonary Disease (COPD)
• Sleep Apnea (Obstructive and Central Types)
• Asthma
• Post-acute Respiratory Failure

A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes chronic obstructive pulmonary disease (COPD), sleep apnea (obstructive and central types), asthma, and post-acute respiratory failure.

Analysis by Region:

• Northeast
• Midwest
• South
• West

The report has also provided a comprehensive analysis of all the major regional markets, which include Northeast, Midwest, South, and West.

Competitive Landscape:

The US at-home respiratory care services market demonstrates a moderately concentrated competitive structure characterized by a mix of large national providers with comprehensive service networks, regional players with strong local market presence, and specialized providers focusing on specific therapeutic areas or patient populations. Competition centers on clinical quality outcomes, service accessibility, technological capabilities, and relationships with referring physicians and healthcare systems. Leading organizations differentiate through integrated care models combining equipment provision, clinical monitoring, patient education, and care coordination services delivered through multidisciplinary teams. The market has witnessed consolidation activity as larger companies acquire regional providers to expand geographic footprint, achieve economies of scale in device procurement and logistics, and enhance capabilities in areas like remote patient monitoring and value-based contracting. Private equity investment has accelerated industry consolidation, with financial sponsors attracted to stable Medicare reimbursement streams, favorable demographic trends, and opportunities to improve operational efficiency through standardization and technology deployment. Innovation focus areas include connected device development, artificial intelligence integration for predictive analytics, telehealth platform enhancement, and data interoperability solutions enabling seamless information exchange across the care continuum.

US At-home Respiratory Care Services Industry Latest Developments:

• January 2025: ResMed launched its FDA-cleared NightOwl home sleep apnea test nationwide across the United States, making diagnostic testing more accessible to patients. The device enables individuals to conduct sleep studies at home without requiring visits to clinical sleep laboratories, addressing the growing demand for convenient, patient-centric diagnostic solutions that reduce healthcare system costs while maintaining clinical accuracy.
• February 2024: ResMed launched the AirCurve 11 series of bilevel-positive airway pressure devices in the US. These devices have integrated digital technology that is intended to increase therapy initiation and maintenance rates for patients with sleep apnea. The launch expanded ResMed's product portfolio as competitor Philips Respironics remained prohibited from selling sleep and respiratory care devices in the US market due to an FDA consent decree.
• October 2024: Modivcare partnered with Tenovi to integrate Adherium's Hailie Smart Inhalers into its chronic condition management platform, combining Tenovi's cellular monitoring technology with Modivcare's clinical services through its VRI and Higi Care subsidiaries. The collaboration provides cost-effective solutions for improving medication adherence among patients with severe asthma and other chronic respiratory conditions, demonstrating the industry's strategic focus on digital health integration.

US At-home Respiratory Care Services Market Report Coverage:

Key Questions Answered in This Report:

• How has the US at-home respiratory care services market performed so far and how will it perform in the coming years?
• What is the breakup of the US at-home respiratory care services market on the basis of therapy?
• What is the breakup of the US at-home respiratory care services market on the basis of indication?
• What is the breakup of the US at-home respiratory care services market on the basis of region?
• What are the various stages in the value chain of the US at-home respiratory care services market?
• What are the key driving factors and challenges in the US at-home respiratory care services market?
• What is the structure of the US at-home respiratory care services market and who are the key players?
• What is the degree of competition in the US at-home respiratory care services market?

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the US at-home respiratory care services market from 2020-2034.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the US at-home respiratory care services market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the US at-home respiratory care services industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.